Previous 10 | Next 10 |
Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed a new board member; Matthew J. Hawryluk, PhD, will “help support the company’s strategic initia...
EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., ( www.predictive-oncology.com ) to its Board of Directors to help support the company’s strategic initiatives and commercializat...
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor confer...
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months – median not yet reached -- -- Patients who achieve a molecular response...
Gritstone Oncology press release ( NASDAQ: GRTS ): Q3 GAAP EPS of -$0.35. Revenue of $3.02M (+15.7% Y/Y). Cash, cash equivalents, marketable securities and restricted cash were $151.8 million as of September 30, 2022, compared to $223.5 million as of December 31, 2021....
-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- -- Initial Phase 2 data from KRAS-directed SLATE ("off-the-shelf" neoantigen program) s...
Gritstone bio ( NASDAQ: GRTS ) gained ~14% on Monday after Piper Sandler initiated its coverage with an Overweight recommendation, noting that the recently announced Phase 1 data for the biotech’s COVID-19 shot validates its vaccine technology for other infectious d...
Gritstone bio ( NASDAQ: GRTS ) on Tuesday said its self-amplifying mRNA (samRNA) COVID vaccine showed tolerability and immunogenicity in two phase 1 trials. CORAL-CEPI : The study includes 340 people and is evaluating T cell-enhanced omicron- and beta-s...
Clinical-stage biotechnology company Gritstone bio ( NASDAQ: GRTS ) will sell 6.6M shares, through private investment in public equity financing, at $2.26 per share. The securities purchase agreement that the company has executed to sell also involves 13.3M pre-funded...
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private inve...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...